News

The need for analytical technology that reveals the effect of production process on CQAs of viral particles in gene therapy and vaccines, and the most common analyses requested.

We at Vironova are delighted to have entered into a collaboration with Testa Center in Uppsala, Sweden! Testa Center is a GE Healthcare subsidiary (GE owns 100%) and a separate business entity running as non-profit and with legal autonomy.

In Gene Therapy, viral vector stability and integrity must be carefully investigated before scaling up production. Specific process steps can be evaluated to understand what impact they have on viral particle integrity. Viral particle...

An example of how Hitachi High Technologies and Vironova AB walk the talk in TEM research and business collaboration.   To achieve great advancement by relying and leveraging on each others core competencies and competitive edge, with sustainable,...

We did it! Today Team Vironova won the People's Choice Finals in Hitachi´s Transformation Awards in Las Vegas.

Accurate and reliable analytics are crucial in the development and manufacturing of viral-based drugs. In this webcast key concepts and strategies will be discussed how to apply analytical information to the development of these emerging therapies.

Characterization and analysis of subvisible particles of biological origin can be challenging or give insufficient information. In this study Adeno associated virus (AAV) particles contaminated by host cell proteasomes are analysed with direct...

The Annual General Meeting of Vironova AB will be held on Monday 24 June 2019 at 15.00, at the Company's premises, at Gävleatan 22, in Stockholm - Sweden.

May 15-17, London, UK, EU

  Best practices from Vironova Biosafety. Vironova Biosafety specialize in viral clearance studies for biological drugs. These kinds of drug products based on live cells have an inherent risk for viral contamination that could cause serious harm or...